Locally Advanced Basal Cell Carcinoma

Also known as: Locally advanced basal cell carcinoma (BCC)

Drug	Drug Name	Drug Description
DB14707	Cemiplimab	A programmed death receptor-1 blocking antibody used to treat cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer.
DB08828	Vismodegib	A hedgehog pathway inhibitor used to treat patients with locally advanced or metastatic basal cell carcinoma.

Drug	Drug Name	Target	Type
DB14707	Cemiplimab	Programmed cell death protein 1	target
DB08828	Vismodegib	Smoothened homolog	target
DB08828	Vismodegib	Cytochrome P450 2C9	enzyme
DB08828	Vismodegib	Cytochrome P450 3A4	enzyme
DB08828	Vismodegib	P-glycoprotein 1	transporter
DB08828	Vismodegib	Cytochrome P450 2C8	enzyme
DB08828	Vismodegib	Cytochrome P450 2C19	enzyme
DB08828	Vismodegib	ATP-binding cassette sub-family G member 2	transporter
DB08828	Vismodegib	Serum albumin	carrier
DB08828	Vismodegib	Alpha-1-acid glycoprotein 1	carrier

Drug	Drug Name	Phase	Status	Count
DB14707	Cemiplimab	2	Recruiting	1
DB09143	Sonidegib	2	Recruiting	1
DB08828	Vismodegib	2	Completed	1
DB08828	Vismodegib	4	Completed	1
DB09143	Sonidegib	Not Available	Recruiting	1
DB08828	Vismodegib	Not Available	Recruiting	1